Insight

$Raul Cordoba: Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma$

Photo generated from www.thelancet.com

Jun 19, 2024, 06:53

Raul Cordoba: Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma

Raul Cordoba shared on X:

“HOT OFF THE PRESS!

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.”

Read further
Source: Raul Cordoba/X

Raúl Córdoba Mascuñano, MD, PhD is a specialist in hematology and hemotherapy. He is the Coordinator of the Lymphoma Unit at University Hospital Fundación Jiménez Díaz, Madrid, Spain. He is the principal investigator for numerous clinical trials for non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia and other chronic lymphoproliferative syndromes. He is a member of the ethical review board at his current workplace.

cancer Cancer research EPCORE NHL-1 Epcoritamab Epcoritamab monotherapy follicular lymphoma lymphoma multicentre study OncoDaily Oncology Raul Cordoba

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage